These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Side effects associated with current and prospective antimigraine pharmacotherapies. González-Hernández A; Marichal-Cancino BA; MaassenVanDenBrink A; Villalón CM Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):25-41. PubMed ID: 29226741 [TBL] [Abstract][Full Text] [Related]
7. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581 [TBL] [Abstract][Full Text] [Related]
8. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments. Villalón CM; VanDenBrink AM Mini Rev Med Chem; 2017; 17(11):928-938. PubMed ID: 27465216 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. De Vries P; Villalón CM; Saxena PR Eur J Pharmacol; 1999 Jun; 375(1-3):61-74. PubMed ID: 10443565 [TBL] [Abstract][Full Text] [Related]
12. Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. Newman-Tancredi A; Conte C; Chaput C; Verrièle L; Audinot-Bouchez V; Lochon S; Lavielle G; Millan MJ Naunyn Schmiedebergs Arch Pharmacol; 1997 Jun; 355(6):682-8. PubMed ID: 9205951 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological synergy: the next frontier on therapeutic advancement for migraine. Blumenfeld A; Gennings C; Cady R Headache; 2012 Apr; 52(4):636-47. PubMed ID: 22221151 [TBL] [Abstract][Full Text] [Related]
14. Basic mechanisms of migraine and its acute treatment. Edvinsson L; Villalón CM; MaassenVanDenBrink A Pharmacol Ther; 2012 Dec; 136(3):319-33. PubMed ID: 22939884 [TBL] [Abstract][Full Text] [Related]
15. The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors. Gupta S; Villalón CM Pharmacol Ther; 2010 Oct; 128(1):170-90. PubMed ID: 20655327 [TBL] [Abstract][Full Text] [Related]
16. Practical considerations for the treatment of elderly patients with migraine. Sarchielli P; Mancini ML; Calabresi P Drugs Aging; 2006; 23(6):461-89. PubMed ID: 16872231 [TBL] [Abstract][Full Text] [Related]
18. Sumatriptan. An updated review of its use in migraine. Perry CM; Markham A Drugs; 1998 Jun; 55(6):889-922. PubMed ID: 9617601 [TBL] [Abstract][Full Text] [Related]
19. Acute management of migraine: triptans and beyond. Diener HC; Limmroth V Curr Opin Neurol; 1999 Jun; 12(3):261-7. PubMed ID: 10499171 [TBL] [Abstract][Full Text] [Related]
20. Advances in pharmacological treatment of migraine. Diener HC; Limmroth V Expert Opin Investig Drugs; 2001 Oct; 10(10):1831-45. PubMed ID: 11772289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]